Justin Stebbing

Protein kinases as targets for cancer treatment.

Germ-cell tumors.

HIV-associated Castleman's disease: from case reports to evidence.

HIV-associated Kaposi sarcoma and gender.

Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.

Brief communication: rituximab in HIV-associated multicentric Castleman disease.

Cardiotoxicity and anthracyclines.

The risks and incidence of K65R and L74V mutations and subsequent virologic responses.

Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma.

HIV-associated multicentric Castleman's disease.

Cancer vaccines: clinical development challenges and proposed regulatory approaches for patient access to promising treatments.

AIDS-associated Kaposi's sarcoma associated with a low viral load and a high CD4 cell count.

The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms.

Use of antidepressants and risk of cancer in individuals infected with HIV.

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

Bendamustine as a model for the activity of alkylating agents.

HIV, hepatitis B and hepatitis C coinfection in Kenya.

Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.

The phosphorylated membrane estrogen receptor and cytoplasmic signaling and apoptosis proteins in human breast cancer.

FLEX data, KRAS and ERCC1 testing in oncology.

Host pharmacogenetics in the treatment of HIV and cancer.

Progression-free versus overall survival and adequate powering in randomised studies.

HIV/AIDS: epidemiology, pathophysiology, and treatment of Kaposi sarcoma-associated herpesvirus disease: Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman disease.

Triple-class antiretroviral agent resistance in a large cohort: prevalence and clinical outcomes.

Human immunodeficiency virus--associated renal cell carcinoma: a transatlantic case series.

Why does cytotoxic chemotherapy cure only some cancers?

Radiological imaging in the context of HIV infection: size of the lesion is not everything.

FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease.

Cetuximab in the first-line therapy of metastatic colorectal carcinoma: not so CRYSTAL clear.

Thyroid dysfunction and relationship to antiretroviral therapy in HIV-positive individuals in the HAART era.

Measurements of EGFR expression on circulating tumor cells are reproducible over time in metastatic breast cancer patients.

Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.

The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies.

Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.

Positioning pemetrexed in the treatment of ovarian cancer.

HIV-1 step study.

The relationship between prolonged antiretroviral therapy and cryptogenic liver disease.

CK1delta modulates the transcriptional activity of ERalpha via AIB1 in an estrogen-dependent manner and regulates ERalpha-AIB1 interactions.

Epstein-Barr virus in Burkitt's lymphoma: the missing link.

The nucleoside backbone affects durability of efavirenz- or nevirapine-based highly active antiretroviral therapy in antiretroviral-naive individuals.

Receptor-based predictors of response in breast cancer.

Not so SMART?

Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia.

Peritoneal disease in breast cancer: a specific entity with an extremely poor prognosis.

A multicentre cohort experience with double-boosted protease inhibitors.

Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease.

Non-AIDS-defining cancers.

Trastuzumab: unusual responses and toxicities.

Epigenetic modifications in AML and MDS.

The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response.

[11C]choline positron emission tomography in estrogen receptor-positive breast cancer.

ELISPOT and functional T cell analyses using HLA mono-specific target cells.

The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.

A meta-analysis of transient elastography for the detection of hepatic fibrosis.

Bevacizumab and surgery: what is the real risk?

Circulating tumour cells as more than prognostic markers.

Lymphoid and histiocytic proliferations in HIV-positive patients: problems in diagnosis.

Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.

Serum molecular signatures of weight change during early breast cancer chemotherapy.

Unique localization of circulating tumor cells in patients with hepatic metastases.

Cryptogenic pseudocirrhosis: a new clinical syndrome of noncirrhotic portal hypertension (unassociated with advanced fibrosis) that can be detected by transient elastography in patients with HIV.

No evidence for a viral association or aetiology in pancreatic cancer.

Clinical utility of circulating tumor cell measurement in the diagnosis of indeterminate lesions of the pancreas.

Kinetic filtering of [(18)F]Fluorothymidine in positron emission tomography studies.

Kinases as targets in the treatment of solid tumors.

Primary esophageal carcinoma in the era of highly active antiretroviral therapy.

Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc.

A single-center cohort experience of raltegravir in salvage patients failing therapy.

PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.

No evidence for a polyomavirus association or aetiology in AIDS-associated nonsmall cell lung cancer.

Schizophrenia does not adversely affect the treatment of women with breast cancer: a cohort study.

Clinical significance of circulating tumor cells.

Circulating sphingosine-1-phosphate inversely correlates with chemotherapy-induced weight gain during early breast cancer.

A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer.

Impact of portal vein embolization on expression of cancer stem cell markers in regenerated liver and colorectal liver metastases.

Cytokine and adhesion molecule expression evolves between the neutrophilic and lymphocytic phases of viral meningitis.

Reproducibility of [11C]choline-positron emission tomography and effect of trastuzumab.

Combining luteinising hormone releasing hormone agonists and aromatase inhibitors in breast cancer.

A trial of caspofungin salvage treatment in PCP pneumonia.

Intramedullary spinal cord metastases in breast cancer are associated with improved longer-term systemic control.

The anti-tumor effects of human immunodeficiency virus protease inhibitors: ready for real time?

Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration.

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer.

A comparison of patients' attitudes to antiretroviral toxicities between the UK and Uganda.

The evolution of coreceptor tropism in HIV-infected patients interrupting suppressive antiretroviral therapy.

Two-stage resection for bilobar colorectal liver metastases: R0 resection is the key.

Circulating tumor cells and plasma DNA analysis in patients with indeterminate early or metastatic breast cancer.

Combination antiretroviral therapy toxicities: a comparison between patients and health care professionals.

Breast cancer (metastatic).

Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease.

The pharmacoeconomics of spiralling cancer drug costs - is there a viable solution?

Outcomes in unresectable and locally advanced resected cholangiocarcinoma.

Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease.

The HVTN 503/Phambili study: efficacy is always the issue.

Epidermal growth factor receptor status in early stage breast cancer is associated with cellular proliferation but not cross-talk.

Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.

Breast Cancer in the Setting of HIV.

LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome.

Lemur tyrosine kinase-3 (LMTK3) in cancer and evolution.

Breast cancer (non-metastatic).

Colorectal cancer in HIV positive individuals: the immunological effects of treatment.

AIDS-Related Pathology.

Biological basis of [¹¹C]choline-positron emission tomography in patients with breast cancer: comparison with [¹⁸F]fluorothymidine positron emission tomography.

Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer.

Use of mathematical models to understand anticancer drug delivery and its effect on solid tumors.

Determination of cut-offs for circulating tumor cell measurement in metastatic cancer.

Antioxidants and cancer.

Genomic analysis of circulating cell-free DNA infers breast cancer dormancy.

[18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.

microRNAs as markers of survival and chemoresistance in pancreatic ductal adenocarcinoma.

Shark cartilage: has the popularisation of science failed?

Improving outcomes in cholangiocarcinomas.

The role of pseudokinases in cancer.

Cell-free DNA as a biomarker in the context of cancer, viruses, and methylation.

Integrated analysis of miRNA and mRNA profiles enables target acquisition in human cancers.

Ginger: the root of cancer therapy?

MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors.

Whole blood stem cell re-infusion and escalated dose melphalan in castration-resistant prostate cancer: a phase 1 study.

Monitoring early response to taxane therapy in advanced breast cancer with circulating tumor cells and [(18)F] 3´-deoxy-3´-fluorothymidine PET: a pilot study.

An overview of drug development for metastatic breast cancer.

The clinical significance of tumor infiltrating lymphoctyes in breast cancer: does subtype matter?

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study.

The clinico-pathologic role of microRNAs miR-9 and miR-151-5p in breast cancer metastasis.

Highlights from the latest articles in breast cancer pharmacogenomics.

miRNAs in breast cancer: ready for real time?

Coffee: the science and art of moderation.

Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy.

Imaging of cellular proliferation in liver metastasis by [18F]fluorothymidine positron emission tomography: effect of therapy.

Retinoblastoma protein determines aggressiveness in triple-negative breast cancer.

The emerging harm of antioxidants in carcinogenesis.

Circulating tumour cells as biomarkers in early breast cancer.

The role of miR-10b in metastatic pancreatic ductal adenocarcinoma.

A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI).

Raising a glass of red wine against cancer, or not?

Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma?

Loss of miR-126 is crucial to pancreatic cancer progression.

Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms?.

Ayurveda: alternative or complementary?

Hide and seek: tell-tale signs of breast cancer lurking in the blood.

Role of miRNAs in the response to anticancer therapy.

Defining a prognostic molecular profile for ductal adenocarcinoma of the pancreas highlights known key signaling pathways.

Is there a role for intravenous iron therapy in patients undergoing colorectal cancer resection?

Towards a clinical use of miRNAs in pancreatic cancer biopsies.

LATS2 is a modulator of estrogen receptor alpha.

Aristolochia: the malignant truth.

MicroRNAs in the cancer clinic.

Deep sequencing of small RNAs identifies canonical and non-canonical miRNA and endogenous siRNAs in mammalian somatic tissues.

The efficacy of axillary ultrasound in the detection of nodal metastasis in breast cancer.

Ginseng: panacea among herbal remedies?

Blood-based miRNAs as noninvasive diagnostic and surrogative biomarkers in colorectal cancer.

miR-23b regulates cytoskeletal remodeling, motility and metastasis by directly targeting multiple transcripts.

Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use.

Chocolate: delicious beauty or harmful beast?

The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study.

Cancer stem cells--therapeutic targeting or therapy?

Circulating peripheral blood mononuclear cells exhibit altered miRNA expression patterns in pancreatic cancer.

The dual function of KSR1: a pseudokinase and beyond.

The p53 miRNA interactome and its potential role in the cancer clinic.

Emerging roles of competing endogenous RNAs in cancer: insights from the regulation of PTEN.

Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.

Downregulation of microRNA-515-5p by the estrogen receptor modulates sphingosine kinase 1 and breast cancer cell proliferation.

Milk thistle: early seeds of potential.

MicroRNA-23b regulates cellular architecture and impairs motogenic and invasive phenotypes during cancer progression.

MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression.

Is the detection of circulating tumor cells in locally advanced pancreatic cancer a useful prognostic marker?

Nuts and cancer: where are we now?

Influence of plasma processing on recovery and analysis of circulating nucleic acids.

Mistletoe: for cancer or just for Christmas?

Cell-free DNA for the detection of pancreatic, liver and upper gastrointestinal cancers: has progress been made?

IDH mutations in tumorigenesis and their potential role as novel therapeutic targets.

Broader implications of a stage-guided stratified therapeutic approach for AIDS-related Kaposi's sarcoma.

MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

A microRNA meta-signature for pancreatic ductal adenocarcinoma.

Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients with pancreatic cancer.

Crystals and cancer: good vibrations or bad intentions?

Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.

miR-15b and miR-17 Are Tumor-Derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia.

Brain metastases associated with germ cell tumors may be treated with chemotherapy alone.

Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets.

Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice.

Patient-derived xenografts for individualized care in advanced sarcoma.

Hyperthermia in cancer: is it coming of age?

The prognostic role of circulating tumor cells in heavily pretreated individuals with a low life expectancy.

Cancer: Where were we, where are we, where are we going.

Growth arrest-specific transcript 5 associated snoRNA levels are related to p53 expression and DNA damage in colorectal cancer.

The kinase LMTK3 promotes invasion in breast cancer through GRB2-mediated induction of integrin β₁.

Reply to S.E. Krown et al.

Exploiting interleukin 6 in multicentric Castleman's disease.

Noncoding RNAs and the control of hormonal signaling via nuclear receptor regulation.

Electrotherapy: enlightening modern medicine.

Circulating free DNA in the management of breast cancer.

Broader implications of SILAC-based proteomics for dissecting signaling dynamics in cancer.

Uncaria tomentosa, the cat's whiskers or claws?

Sphingosine kinase 1 contributes to leptin-induced STAT3 phosphorylation through IL-6/gp130 transactivation in oestrogen receptor-negative breast cancer.

Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway.

Whole genome sequence analysis suggests intratumoral heterogeneity in dissemination of breast cancer to lymph nodes.

Black cohosh, hot flushes, and breast cancer.

Activating mutations of GNAS and KRAS in cystic fluid can help detect intraductal papillary mucinous neoplasms of the pancreas.

Genetic variants and response to cancer treatments.

The germline of the malaria mosquito produces abundant miRNAs, endo-siRNAs, piRNAs and 29-nt small RNAs.